MX353874B - Gotas para los ojos que contienen diquafosol. - Google Patents
Gotas para los ojos que contienen diquafosol.Info
- Publication number
- MX353874B MX353874B MX2014011468A MX2014011468A MX353874B MX 353874 B MX353874 B MX 353874B MX 2014011468 A MX2014011468 A MX 2014011468A MX 2014011468 A MX2014011468 A MX 2014011468A MX 353874 B MX353874 B MX 353874B
- Authority
- MX
- Mexico
- Prior art keywords
- eye drop
- diquafosol
- production
- during
- chelating agent
- Prior art date
Links
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 title abstract 6
- 229950003529 diquafosol Drugs 0.000 title abstract 6
- 239000003889 eye drop Substances 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 abstract 6
- 239000002738 chelating agent Substances 0.000 abstract 4
- 230000001954 sterilising effect Effects 0.000 abstract 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract 3
- 206010015946 Eye irritation Diseases 0.000 abstract 2
- 230000006866 deterioration Effects 0.000 abstract 2
- 231100000013 eye irritation Toxicity 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 238000003860 storage Methods 0.000 abstract 2
- 238000009826 distribution Methods 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En una gota para ojos con Diquafosol que contiene un agente quelante a una concentración de 0.0001 hasta 1% (p/v), la producción de precipitados insolubles durante el almacenamiento, lo cual por lo general se observa en una gota para ojos con Diquafosol, y se puede evitar el deterioro en el desempeño de filtrado durante un proceso de producción (un proceso de esterilización por filtro). En una gota para ojos con Diquafosol que contiene un agente quelante, se observan la reducción en la irritación ocular y la mejora en la eficacia de conservación en comparación con aquellas en una gota para ojos con Diquafosol que no contienen ningún agente quelante. Por lo tanto, en la presente invención, se pueden alcanzar propiedades fisicoquímicas estables durante el curso de producción y distribución y durante el curso de almacenamiento por un paciente, y se observan la reducción en la irritación ocular y la mejora en la eficacia de conservación. En particular, en una gota para ojos con Diquafosol que contiene un agente quelante, se evita el deterioro en el desempeño de filtrado durante un proceso de producción (un proceso de esterilización por filtro). Por lo tanto, se puede alcanzar una esterilización por filtro bastante eficiente durante el curso de producción, lo cual contribuye a la reducción en el costo de producción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012069157 | 2012-03-26 | ||
| PCT/JP2013/058519 WO2013146649A1 (ja) | 2012-03-26 | 2013-03-25 | ジクアホソル含有点眼液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011468A MX2014011468A (es) | 2015-01-12 |
| MX353874B true MX353874B (es) | 2018-02-01 |
Family
ID=49259901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011468A MX353874B (es) | 2012-03-26 | 2013-03-25 | Gotas para los ojos que contienen diquafosol. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9486529B2 (es) |
| EP (2) | EP2832359B1 (es) |
| JP (6) | JP5625081B2 (es) |
| KR (5) | KR101875845B1 (es) |
| CN (2) | CN104203254A (es) |
| AU (3) | AU2013241507A1 (es) |
| BR (1) | BR112014023402B1 (es) |
| CA (1) | CA2868390C (es) |
| DK (1) | DK2832359T3 (es) |
| EA (1) | EA028848B1 (es) |
| ES (1) | ES2702575T3 (es) |
| GE (1) | GEP20166470B (es) |
| HK (1) | HK1204922A1 (es) |
| HU (1) | HUE041671T2 (es) |
| IN (1) | IN2014DN08632A (es) |
| MX (1) | MX353874B (es) |
| MY (1) | MY169816A (es) |
| NZ (1) | NZ631041A (es) |
| PH (1) | PH12014501955B1 (es) |
| PL (1) | PL2832359T3 (es) |
| PT (1) | PT2832359T (es) |
| SG (2) | SG10201607872PA (es) |
| TR (1) | TR201820073T4 (es) |
| TW (4) | TWI625135B (es) |
| UA (1) | UA113981C2 (es) |
| WO (1) | WO2013146649A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2750229B2 (ja) | 1991-05-30 | 1998-05-13 | 信越石英株式会社 | 大型軽量化反射鏡 |
| JP2750234B2 (ja) | 1991-12-25 | 1998-05-13 | 信越石英株式会社 | シリカ質軽量反射鏡の製造方法 |
| MY169816A (en) * | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| MX2016009049A (es) * | 2014-01-10 | 2016-09-09 | Santen Pharmaceutical Co Ltd | Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico. |
| MX384935B (es) * | 2014-12-25 | 2025-03-14 | Santen Pharmaceutical Co Ltd | Solucion oftalmica acuosa. |
| JP6104433B2 (ja) * | 2015-06-05 | 2017-03-29 | 参天製薬株式会社 | 水性点眼液 |
| HK1245651A1 (en) * | 2015-06-05 | 2018-08-31 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens |
| JPWO2017002827A1 (ja) | 2015-06-29 | 2018-04-26 | ヤマサ醤油株式会社 | Ｐ１，ｐ４−ビス（５’−ウリジル）テトラホスフェート結晶の保管方法 |
| JP6688057B2 (ja) * | 2015-12-01 | 2020-04-28 | 日水製薬株式会社 | グラム染色用後染色試液及びグラム染色方法 |
| KR102472773B1 (ko) * | 2018-02-28 | 2022-11-30 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물 |
| CN108403625A (zh) * | 2018-04-11 | 2018-08-17 | 东莞解石医药科技有限公司 | 一种含有螯合剂的地夸磷索四钠滴眼液 |
| WO2020046950A1 (en) * | 2018-08-30 | 2020-03-05 | Eyevance Pharmaceuticals Llc | Ocular lubricant formulations |
| KR102656181B1 (ko) * | 2019-08-27 | 2024-04-08 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물 |
| CN113720924B (zh) * | 2020-05-25 | 2025-01-10 | 南京帝昌医药科技有限公司 | 一种地夸磷索四钠的含量及有关物质检测方法 |
| JPWO2022107791A1 (es) * | 2020-11-18 | 2022-05-27 | ||
| WO2022107790A1 (ja) * | 2020-11-18 | 2022-05-27 | 参天製薬株式会社 | アルキルジアミノエチルグリシンまたはその塩を含有する水性点眼液 |
| KR102548710B1 (ko) | 2020-12-24 | 2023-06-28 | 주식회사 종근당 | 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물 |
| CN112933040A (zh) * | 2021-02-04 | 2021-06-11 | 合肥博思科创医药科技有限公司 | 一种舒更葡糖钠注射液的制备方法 |
| WO2023195718A1 (ko) * | 2022-04-04 | 2023-10-12 | 서울대학교산학협력단 | 감미 억제용 조성물 및 식품의 감미 억제 방법 |
| KR102794468B1 (ko) * | 2022-04-04 | 2025-04-14 | 서울대학교산학협력단 | 감미 억제용 조성물 및 식품의 감미 억제 방법 |
| JP7735925B2 (ja) * | 2022-05-02 | 2025-09-09 | 株式会社三洋物産 | 遊技機 |
| CN116019767A (zh) * | 2023-01-12 | 2023-04-28 | 上海阿尔福斯医药科技有限公司 | 眼用制剂及其制备方法 |
| CN117838628B (zh) * | 2024-03-01 | 2024-05-28 | 广州市桐晖药业有限公司 | 一种地夸磷索钠滴眼液及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH075456B2 (ja) * | 1988-10-01 | 1995-01-25 | 参天製薬株式会社 | 点眼液 |
| JP2530491B2 (ja) | 1988-12-20 | 1996-09-04 | 参天製薬株式会社 | ヒアルロン酸点眼液 |
| TW200402B (es) | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
| US5504113A (en) | 1994-03-02 | 1996-04-02 | Allergan, Inc. | Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug |
| US5900407A (en) | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| PT981534E (pt) | 1997-02-06 | 2006-09-29 | Inspire Pharmaceuticals Inc | Dinucleotidos e suas utilizacoes |
| EP1012154B1 (en) | 1997-07-25 | 2004-03-17 | Inspire Pharmaceuticals, Inc. | Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof |
| KR19990074047A (ko) | 1998-03-03 | 1999-10-05 | 김수복 | 콘택트렌즈용 세척, 소독 및 보존제 조성물 |
| CN1133432C (zh) | 1998-08-21 | 2004-01-07 | 千寿制药株式会社 | 含水液体药物组合物 |
| JP4880808B2 (ja) * | 1999-11-15 | 2012-02-22 | 久光製薬株式会社 | 人工涙液型点眼剤組成物 |
| JP4003008B2 (ja) * | 2000-05-30 | 2007-11-07 | 参天製薬株式会社 | 角膜上皮伸展促進剤 |
| KR100832821B1 (ko) * | 2000-05-30 | 2008-05-28 | 산텐 세이야꾸 가부시키가이샤 | 각막 상피 신장 촉진제 |
| US6555675B2 (en) * | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| US6583181B1 (en) | 2000-11-22 | 2003-06-24 | Lonza Inc. | Antimicrobial quaternary ammonium compositions with reduced ocular irritation |
| CN1228053C (zh) * | 2001-09-11 | 2005-11-23 | 参天制药株式会社 | 含有二尿苷磷酸的滴眼液 |
| JP2003160491A (ja) * | 2001-09-11 | 2003-06-03 | Santen Pharmaceut Co Ltd | ジウリジンリン酸含有点眼液 |
| WO2003030892A1 (en) | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
| PT1468697E (pt) | 2003-04-14 | 2008-03-05 | Wyeth Corp | Composições contendo piperacilina e tazobactam úteis para injecção |
| JP4806956B2 (ja) | 2004-04-20 | 2011-11-02 | 大正製薬株式会社 | 点眼用液剤 |
| US20060073172A1 (en) | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
| CN101060846A (zh) | 2004-12-02 | 2007-10-24 | 维纳斯药业有限公司 | 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分 |
| KR100870104B1 (ko) * | 2005-11-28 | 2008-11-26 | 주식회사 머젠스 | 안구건조증 치료 및 예방용 조성물 |
| JP4168071B2 (ja) | 2005-12-08 | 2008-10-22 | 興和株式会社 | 点眼用組成物 |
| JP2008247828A (ja) | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| CN100534423C (zh) * | 2007-11-30 | 2009-09-02 | 张咏梅 | 一种保质期长的氯霉素滴眼液及其制备方法 |
| US8119112B2 (en) | 2008-01-31 | 2012-02-21 | Bausch & Lomb Incorporated | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid |
| CN101461778A (zh) * | 2009-01-06 | 2009-06-24 | 河北科技大学 | 不含抑菌剂的盐酸环丙沙星滴眼液及其制备方法 |
| EP2393355A4 (en) * | 2009-01-23 | 2012-07-25 | Inspire Pharmaceuticals Inc | METHOD FOR TREATING A DRY EYE WITH AZITHROMYCIN |
| CN102100693A (zh) * | 2009-12-16 | 2011-06-22 | 沈阳兴齐制药有限公司 | 一种含有肌肽的人工泪液及其制备方法 |
| KR20110104367A (ko) | 2010-03-16 | 2011-09-22 | 삼천당제약주식회사 | 무보존제 안과용 조성물 |
| MY173215A (en) | 2010-07-21 | 2020-01-06 | Cumberland Pharmaceuticals Inc | Acetylcysteine compositions and methods of use thereof |
| PH12013500424B1 (en) | 2010-09-10 | 2018-07-11 | Santen Pharmaceutical Co Ltd | Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof |
| MY161032A (en) * | 2010-12-28 | 2017-04-03 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate |
| CN103596572A (zh) * | 2011-04-12 | 2014-02-19 | 株式会社·R-技术上野 | 水性眼用组合物 |
| MY169816A (en) * | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| NZ631279A (en) | 2012-03-26 | 2016-06-24 | Dilafor Ab | Method for treatment of labor arrest |
-
2013
- 2013-03-25 MY MYPI2014002576A patent/MY169816A/en unknown
- 2013-03-25 TW TW102110422A patent/TWI625135B/zh active
- 2013-03-25 BR BR112014023402-7A patent/BR112014023402B1/pt not_active IP Right Cessation
- 2013-03-25 TW TW109100132A patent/TWI723722B/zh active
- 2013-03-25 EP EP13770386.4A patent/EP2832359B1/en active Active
- 2013-03-25 CA CA2868390A patent/CA2868390C/en active Active
- 2013-03-25 EA EA201491771A patent/EA028848B1/ru unknown
- 2013-03-25 PL PL13770386T patent/PL2832359T3/pl unknown
- 2013-03-25 EP EP18193430.8A patent/EP3431092A1/en not_active Withdrawn
- 2013-03-25 KR KR1020157004372A patent/KR101875845B1/ko not_active Ceased
- 2013-03-25 TW TW109124203A patent/TWI757799B/zh active
- 2013-03-25 MX MX2014011468A patent/MX353874B/es active IP Right Grant
- 2013-03-25 CN CN201380016616.1A patent/CN104203254A/zh active Pending
- 2013-03-25 PT PT13770386T patent/PT2832359T/pt unknown
- 2013-03-25 AU AU2013241507A patent/AU2013241507A1/en not_active Abandoned
- 2013-03-25 HK HK15105452.3A patent/HK1204922A1/xx unknown
- 2013-03-25 US US14/386,169 patent/US9486529B2/en not_active Expired - Fee Related
- 2013-03-25 CN CN202110358504.0A patent/CN113018259A/zh active Pending
- 2013-03-25 DK DK13770386.4T patent/DK2832359T3/en active
- 2013-03-25 HU HUE13770386A patent/HUE041671T2/hu unknown
- 2013-03-25 TR TR2018/20073T patent/TR201820073T4/tr unknown
- 2013-03-25 KR KR1020187037979A patent/KR20190002751A/ko not_active Ceased
- 2013-03-25 WO PCT/JP2013/058519 patent/WO2013146649A1/ja not_active Ceased
- 2013-03-25 KR KR1020207022714A patent/KR20200096708A/ko not_active Ceased
- 2013-03-25 JP JP2013062270A patent/JP5625081B2/ja active Active
- 2013-03-25 IN IN8632DEN2014 patent/IN2014DN08632A/en unknown
- 2013-03-25 TW TW106124911A patent/TWI692364B/zh active
- 2013-03-25 GE GEAP201313609A patent/GEP20166470B/en unknown
- 2013-03-25 KR KR1020147028142A patent/KR101536885B1/ko not_active Ceased
- 2013-03-25 KR KR1020187018799A patent/KR101935484B1/ko not_active Ceased
- 2013-03-25 SG SG10201607872PA patent/SG10201607872PA/en unknown
- 2013-03-25 NZ NZ631041A patent/NZ631041A/en not_active IP Right Cessation
- 2013-03-25 ES ES13770386T patent/ES2702575T3/es active Active
- 2013-03-25 SG SG11201405799TA patent/SG11201405799TA/en unknown
- 2013-03-25 UA UAA201411576A patent/UA113981C2/uk unknown
-
2014
- 2014-04-14 JP JP2014082821A patent/JP6126041B2/ja active Active
- 2014-09-01 PH PH12014501955A patent/PH12014501955B1/en unknown
-
2016
- 2016-02-23 AU AU2016201110A patent/AU2016201110B2/en not_active Ceased
- 2016-02-23 AU AU2016201111A patent/AU2016201111A1/en not_active Withdrawn
- 2016-10-10 US US15/289,273 patent/US10071113B2/en active Active
-
2017
- 2017-04-05 JP JP2017075167A patent/JP6389544B2/ja active Active
-
2018
- 2018-02-07 JP JP2018020154A patent/JP6483299B2/ja active Active
- 2018-08-14 US US16/103,328 patent/US10632139B2/en not_active Expired - Fee Related
-
2019
- 2019-02-12 JP JP2019022692A patent/JP7042762B2/ja active Active
-
2020
- 2020-03-16 US US16/819,974 patent/US11166974B2/en not_active Expired - Fee Related
-
2022
- 2022-03-14 JP JP2022039183A patent/JP7447176B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX353874B (es) | Gotas para los ojos que contienen diquafosol. | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| PH12015500561A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| PH12015500115A1 (en) | Glucagon analogues | |
| IN2015DN01156A (es) | ||
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| IN2012DN03312A (es) | ||
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| WO2015061632A3 (en) | Antimicrobial compositions and articles | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| MY161032A (en) | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate | |
| MY178888A (en) | Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same | |
| EA201492081A1 (ru) | (r)-нифурател, его применение в лечении инфекций и синтез (r)- и (s)-нифуратела | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
| PH12018501624A1 (en) | A composition comprising pic for treatment of cancer | |
| MY182591A (en) | Compositions for use in treating eye disorders using dipyridamole | |
| NZ707081A (en) | Agent for preventing or improving decline in brain function | |
| EA033769B9 (ru) | Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем | |
| PH12015500070A1 (en) | Pediatric oral liquid compositions containing nepadutant | |
| WO2014031982A3 (en) | Methods and compositions for treating pain | |
| MX380088B (es) | Uso terapéutico de una solución oftálmica acuosa estéril. | |
| NZ631362A (en) | Arry-520 for use in treating cancer in a patient with low aag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |